Biogen Inc

NASDAQ:BIIB  
206.05
+1.83 (+0.90%)
4:04:39 PM EDT: $206.98 +0.93 (+0.45%)
Products

Biogen Submits Final Protocol For Aduhelm Phase 4 Envision Trial To FDA

Published: 03/30/2022 11:44 GMT
Biogen Inc (BIIB) - Biogen Submits Final Protocol for Aduhelm (aducanumab-avwa) Phase 4 Envision Trial to FDA.
Biogen Inc - Confirmatory Trial's Completion is Expected in an Accelerated Timeline of Four Years With Patient Screening to Start in May.
Biogen Inc - Reaffirmed Trial's Goal of Recruiting at Least 18 Percent of Patients in U.S. From Black/african American and Latino Communities.